Clinical Trials Logo

Filter by:
NCT ID: NCT02914600 Terminated - Crohn's Disease Clinical Trials

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

DIVERSITYLTE
Start date: March 17, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).

NCT ID: NCT02914561 Completed - Crohn's Disease Clinical Trials

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

DIVERSITY1
Start date: October 31, 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term extension (LTE) study (Study GS-US-419-3896).

NCT ID: NCT02893280 Withdrawn - Clinical trials for Acute Coronary Syndrome

Acute Coronary Syndrome Sri Lanka Audit Project

ACSSLAP
Start date: April 2015
Phase: N/A
Study type: Observational

ACSSLAP is the first island wide audit project in Sri Lanka on ACS.

NCT ID: NCT02837523 Withdrawn - Hypophosphatemia Clinical Trials

Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)

BioCystinosis
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Cystinosis disease from the blood

NCT ID: NCT02778295 Withdrawn - Clinical trials for Chronic Kidney Disease

Biomarker for Patients With Fabry Disease (BioFabry)

BioFabry
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood

NCT ID: NCT02747927 Active, not recruiting - Healthy Volunteers Clinical Trials

Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

TIDES
Start date: September 7, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 4 to 16 year old participants.

NCT ID: NCT02718222 Completed - Contraception Clinical Trials

Impact and Performance of Institutionalizing Immediate Post-partum IUD Services

Start date: September 2015
Phase: N/A
Study type: Interventional

Studying the impact and performance of institutionalizing immediate post-partum IUD services as a routine part of antenatal counselling and delivery room services in Sri Lanka, Tanzania, and Nepal.

NCT ID: NCT02718027 Terminated - Clinical trials for Nephritis, Hereditary

Biomarker for Alport Syndrome (BioAlport)

BioAlport
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

NCT ID: NCT02712138 Withdrawn - Hyperbilirubinemia Clinical Trials

Biomarker for Gilbert Disease (BioGilbert)

BioGilbert
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Gilbert disease from blood

NCT ID: NCT02710383 Terminated - Pancreatitis Clinical Trials

Biomarker for Cystic Fibrosis

BioCyFi
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to identify biomarker/s for Cystic fibrosis and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s